CD38 expression is an important prognostic marker in diffuse large B‐cell lymphoma
Fumiya Wada, Yoshimitsu Shimomura, Tomohiro Yabushita, Daisuke Yamashita, Aya Ohno, Hiroharu Imoto, Hayato Maruoka, Shigeo Hara, Takayuki Ishikawa
Abstract
Abstract Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous group of diseases with variable outcomes. Although several prognostic markers have been developed, specific biomarkers for stratifying treatment strategies have not been fully investigated. This study aimed to analyze the clinical impact of the expression of cluster of differentiation (CD) 38, which is associated with cellular proliferation and disease progression, in patients with de‐novo DLBCL. Using flow cytometry analysis, 137 cases with DLBCL were investigated for surface expression of CD38. Based on the cut‐off value by the survival classification and regression tree analysis, the patients were categorized into a CD38 HIGH group ( n = 37) and CD38 LOW group ( n = 100). The 4‐years progression‐free survival (PFS) was 31.6% in the CD38 HIGH group and 60.7% in the CD38 LOW group ( p < 0.001). Multivariate analysis showed the CD38 HIGH group to be associated with significantly worse PFS (adjusted hazard ratio [aHR], 2.15, 95% CI: 1.26–3.68, p = 0.005) and poor overall survival (OS) (aHR, 2.54, 95% CI: 1.25–5.19, p = 0.010) than the CD38 LOW group. In conclusion, we demonstrated that high CD38 expression is an independent adverse prognostic factor associated with poor clinical outcomes compared to low CD38 expression. CD38 expression in DLBCL cells might be useful for predicting outcomes and designing risk‐adapted therapies for patients with de‐novo DLBCL.